New shot could simplify prostate cancer treatment
NCT ID NCT07005154
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metastatic hormone-sensitive or castration-resistant prostate cancer will take part to see if the injection works as well or better and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP5541 (an injectable form of abiraterone acetate)
What this could lead to
If it works, this could offer a more convenient, longer-lasting treatment option for advanced prostate cancer, reducing the need for daily pills.
What could go wrong
This is a phase 2 trial, so it's still early. The drug may not work better than current treatments, and side effects like hormone-related issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Associated Urological Specialists
RECRUITINGChicago Ridge, Illinois, 60415, United States
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
Clearview Cancer Institute
RECRUITINGHuntsville, Alabama, 35805, United States
-
H. Lee Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Harasanshin Hospital
RECRUITINGFukuoka, Japan
-
Huai'an First People's Hospital
RECRUITINGHuaian, 211731, China
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, Japan
-
New Mexico Oncology Hematology Consultants
RECRUITINGAlbuquerque, New Mexico, 87109, United States
-
Nippon Medical School Hospital
RECRUITINGBunkyo-ku, Tokyo, Japan
-
Ochsner Health - Ochsner Medical Center - New Orleans
RECRUITINGNew Orleans, Louisiana, 70121, United States
-
Osaka International Cancer Institute
RECRUITINGOsaka, Japan
-
PanOncology Trials
RECRUITINGSan Juan, Puerto Rico
-
Renji Hospital Shanghai Jiaotong Univ School of Medicine
RECRUITINGShanghai, 200127, China
-
Shizuoka Cancer Center
RECRUITINGSunto-gun, Shizuoka, Japan
-
Site DE49001
RECRUITINGHeinsberg, Germany
-
Site DE49004
RECRUITINGNürtingen, Baden-Wurttemberg, Germany
-
Site ES34006
RECRUITINGBarcelona, Catalonia, Spain
-
Site FR33004
RECRUITINGStrasbourg, France
-
Site GB44003
RECRUITINGLondon, United Kingdom
-
Site KR82002
RECRUITINGSeoul, South Korea
-
Site KR82003
RECRUITINGSeoul, South Korea
-
Site KR82004
RECRUITINGSeoul, South Korea
-
Site KR82007
RECRUITINGSeoul, South Korea
-
Site KR82008
RECRUITINGGwangju, South Korea
-
Site TW88602
RECRUITINGTaipei, Taiwan
-
Site TW88603
RECRUITINGKaohsiung City, Taiwan
-
Solaris Health - The Urology Group
RECRUITINGCincinnati, Ohio, 45212, United States
-
Subei People's Hospital
RECRUITINGYangzhou, Jiangsu, 225001, China
-
Tennessee Oncology Nashville
RECRUITINGNashville, Tennessee, 37203, United States
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto, Tokyo, Japan
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, Tianjin Municipality, 300211, China
-
UW Health Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22908-07, United States